Pregabalin is effective on herpetic neuralgia, but whether can prevention post-herpetic neuralgia still need to confirm.
Pregabalin has been recommended as the first-line drug for post-herpetic neuralgia (PHN) therapy currently due to its efficacy and safety. However,there was no valuable report at present on the clinical efficacy of pregabalin for acute and subacute herpetic neuralgia (SHN), expect for a smaller study which included 29 outpatients who had acute zoster pain for a period of 7-1 4 days. And it is not clear whether early application of pregabalin can reduce the incidence of PHN. Therefore, this study was rational designed to evaluate the efficacy and safety of pregabalin in the treatment of herpetic neuralgia，and follow-up to the 8 months, evaluation whether impacting the accidence of PHN. It is the first time in the international that treating acute herpetic neuralgia (AHN) and SHN with pregabalin as a large sample size clinical trial. The results of this study will be great significance for guiding the clinical medication.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Enrollment
342
Pregabalin was taken 300mg,q 12h for 6 month.
Gabapentin was taken 0.4, tid for 6 month.
National drug clinical trial fundation
Guangzhou, Guangdong, China
the changes of numerical rating scale (NRS)
Pain intensity was rated on an 1 1-point numerical rating scale
Time frame: from the date of start to 8 month
Brief Pain Inventory (BPI)
quality of life was rated on Brief Pain Inventory
Time frame: baseline and 8th month
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.